0.44 (-%)
As of Nov 21, 2024
Source:
We are a clinical-and commercial-stage biopharmaceutical company developing therapeutics that address important unmet medical needs. We are currently active in two areas: the development of RNA delivery technology and therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ platforms; AM-401 for the treatment of KRAS driven cancer, AM-411 for the treatment of rheumatoid arthritis; preclinical), and nasal sprays for protection against airborne allergens, and where approved, viruses (Bentrio ; commercial) or the treatment of vertigo (AM-125; Phase 2).
| Country | Bermuda |
| Headquarters | hamilton hm 11 |
| Phone Number | 41 (0) 41 729 71 94 |
| Industry | manufacturing |
| CEO | Thomas Meyer |
| Website | altamiratherapeutics.com |